Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis

References

• Gudmundsson KG, Jónsson T, Arngrímsson R. Guillaume Dupuytren and finger contractures. Lancet. 2003;362(9378):165–168. doi:10.1016/S0140-6736(03)13871-8
   Web of Science ®Google Scholar
• Picardo NE, Khan WS. Advances in the understanding of the aetiology of Dupuytren’s disease. Surgeon. 2012;10(3):151–158.
   PubMed Web of Science ®Google Scholar
• DiBenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study. Hand (NY). 2011;6(2):149–158.
   Google Scholar
• Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren’s contracture. J Bone Joint Surg Br. 1997;79(2):206–210.
   PubMedGoogle Scholar
• Gamstedt A, Holm-Glad J, Ohlson C-G, Sundström M. Hand abnormalities are strongly associated with the duration of diabetes mellitus. J Intern Med. 1993;234(2):189–193. doi:10.1111/j.1365-2796.1993.tb00729.x
   Web of Science ®Google Scholar
• Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren’s disease. J Bone Joint Surg Br. 1984;66(3):322–325. doi:10.1302/0301-620X.66B3.6725338
   PubMedGoogle Scholar
• Wilburn J, McKenna SP, Perry-Hinsley D, Bayat A. The impact of Dupuytren disease on patient activity and quality of life. J Hand Surg Am. 2013;38(6):1209–1214. doi:10.1016/j.jhsa.2013.03.036
   PubMed Web of Science ®Google Scholar
• Engstrand C, Borén L, Liedberg GM. Evaluation of activity limitation and digital extension in Dupuytren’s contracture three months after fasciectomy and hand therapy interventions. J Hand Ther. 2009;22(1):21–26; quiz 27. doi:10.1016/j.jht.2008.08.003
   Web of Science ®Google Scholar
• Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren disease. Nat Rev Rheumatol. 2010;6(12):715–726. doi:10.1038/nrrheum.2010.180
   PubMed Web of Science ®Google Scholar
• Lipman MD, Carstensen SE, Deal DN. Trends in the treatment of Dupuytren disease in the United States between 2007 and 2014. Hand (N Y). 2017;12(1):13–20. doi:10.1177/1558944716647101
   Google Scholar
• Brazzelli M, Cruickshank M, Tassie E, et al. Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation. Health Technol Assess. 2015;19(90):1–202. doi:10.3310/hta19900
   Web of Science ®Google Scholar
• Xiaflex® (collagenase clostridium histolyticum) for injection, for intralesional use [Package insert]. Malvern, PA: Endo Pharmaceuticals Inc; 2019.
   Google Scholar
• Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361(10):968–979. doi:10.1056/NEJMoa0810866
   PubMed Web of Science ®Google Scholar
• Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am. 2010;35(12):2027–2038.
   PubMed Web of Science ®Google Scholar
• Donga P, DeKoven M, Kaplan FT, Tursi JP, Lee WC. Costs of collagenase clostridium histolyticum and fasciectomy for Dupuytren’s contracture. Am J Pharm Benefits. 2015;7(1):24–31.
   Google Scholar
• Sanjuan Cerveró R, Ferrando NF, Jornet JP. Use of resources and costs associated with the treatment of Dupuytren’s contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase clostridium hystolyticum versus subtotal fasciectomy. BMC Musculoskelet Disord. 2013;14:293. doi:10.1186/1471-2474-14-293
   PubMed Web of Science ®Google Scholar
• Povlsen B, Shields AM, Bhabra GS. Resource utilisation associated with single digit Dupuytren’s contracture treated with either surgery or injection of collagenase clostridium histolyticum. Hand Surg. 2014;19(2):205–209.
   PubMedGoogle Scholar
• Mehta S, Belcher HJ. A single-centre cost comparison analysis of collagenase injection versus surgical fasciectomy for Dupuytren’s contracture of the hand. J Plast Reconstr Aesthet Surg. 2014;67(3):368–372.
   Web of Science ®Google Scholar
• Atroshi I, Strandberg E, Lauritzson A, Ahlgren E, Waldén M. Costs for collagenase injections compared with fasciectomy in the treatment of Dupuytren’s contracture: a retrospective cohort study. BMJ Open. 2014;4(1):e004166.
   PubMed Web of Science ®Google Scholar
• Camper SB, Divino V, Hurley D, DeKoven M. Cost per episode of care with Collagenase clostridium histolyticum versus fasciectomy for Dupuytren contracture: a real-world claims database analysis. J Hand Surg Glob Online. 2019;1(2):57–64.
   Google Scholar
• Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(suppl 2):69–80.
   PubMed Web of Science ®Google Scholar
• De Salas-Cansado M, Cuadros M, Del Cerro M, Arandes JM. Budget impact analysis in Spanish patients with Dupuytren’s contracture: fasciectomy vs. collagenase Clostridium histolyticum. Chir Main. 2013;32(2):68–73. doi:10.1016/j.main.2013.02.012
   PubMedGoogle Scholar
• Sefton AK, Smith BJ, Stewart DA. Cost comparison of collagenase clostridium histolyticum and fasciectomy for treatment of Dupuytren’s contracture in the Australian Health System. J Hand Surg Asian Pac Vol. 2018;23(3):336–341. doi:10.1142/S2424835518500327
   Web of Science ®Google Scholar
• Leafblad ND, Wagner E, Wanderman NR, et al. Outcomes and direct costs of needle aponeurotomy, collagenase injection, and fasciectomy in the treatment of Dupuytren contracture. J Hand Surg Am. 2019;44(11):919–927.
   PubMed Web of Science ®Google Scholar
• Hindocha S. Risk factors, disease associations, and Dupuytren diathesis. Hand Clin. 2018;34(3):307–314.
   PubMed Web of Science ®Google Scholar